Cipla (CIPLA.NS) Financial Analysis & Valuation | Quarter Chart
Cipla (CIPLA.NS)
CIPLA.NSPrice: $16.96
Fair Value: 🔒
🔒score
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypert... more
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in Ind... more
Description
Shares
| Market Cap | $13.70B | Exchange | NSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | IN | CEO | Umang Vohra |
| IPO Date | 1996-01-01 | CAGR | 0.14% |
| Employees | 27,764 | Website | www.cipla.com |
| Div. Yield | 26.17% | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | 26.17% |
CIPLA.NS chart loading...
Fundamentals
Technicals
| Enterprise Value | $1215.11B | P/E Ratio | 22.74 |
| Forward P/E | 23.76 | PEG Ratio | -0.41 |
| P/S Ratio | 0.18 | P/B Ratio | 0.16 |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $0.75 | EPS Growth 1Y | 25.29% |
| EPS Growth 3Y | 116.59% | EPS Growth 5Y | 227.11% |
| Revenue Growth 1Y | 6.19% | Gross Margin | 0.67% |
| Operating Margin | 0.39% | Profit Margin | 0.2% |
| ROE | 0.18% | ROA | — |
| ROCE | — | Current Ratio | — |
| Quick Ratio | — | Cash Ratio | — |
| Debt/Equity | — | Interest Coverage | 182.7 |
| Altman Z Score | — | Piotroski Score | 4 |